A196300 Stock Overview
A bio-venture company, engages in the manufacture and sale of peptide biomaterials and drug raw materials in South Korea and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Anygen Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩6,810.00 |
| 52 Week High | ₩17,670.00 |
| 52 Week Low | ₩6,300.00 |
| Beta | 0.68 |
| 1 Month Change | -41.55% |
| 3 Month Change | -52.21% |
| 1 Year Change | -57.96% |
| 3 Year Change | -37.24% |
| 5 Year Change | -33.56% |
| Change since IPO | -45.95% |
Recent News & Updates
Does Anygen (KOSDAQ:196300) Have A Healthy Balance Sheet?
Dec 16
Would Anygen (KOSDAQ:196300) Be Better Off With Less Debt?
Aug 29Recent updates
Does Anygen (KOSDAQ:196300) Have A Healthy Balance Sheet?
Dec 16Would Anygen (KOSDAQ:196300) Be Better Off With Less Debt?
Aug 29Does Anygen's (KOSDAQ:196300) Share Price Gain of 86% Match Its Business Performance?
Mar 11Is Anygen (KOSDAQ:196300) Using Too Much Debt?
Jan 17
Should Anygen (KOSDAQ:196300) Be Disappointed With Their 64% Profit?
Nov 24Shareholder Returns
| A196300 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -34.2% | 3.0% | 0.2% |
| 1Y | -58.0% | 30.7% | -4.9% |
Return vs Industry: A196300 underperformed the KR Biotechs industry which returned 30.7% over the past year.
Return vs Market: A196300 underperformed the KR Market which returned -4.9% over the past year.
Price Volatility
| A196300 volatility | |
|---|---|
| A196300 Average Weekly Movement | 12.7% |
| Biotechs Industry Average Movement | 8.8% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in KR Market | 13.0% |
| 10% least volatile stocks in KR Market | 3.5% |
Stable Share Price: A196300's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: A196300's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | n/a | Jae Il Kim | www.anygen.com |
Anygen Co., Ltd., a bio-venture company, engages in the manufacture and sale of peptide biomaterials and drug raw materials in South Korea and internationally. It develops GMP, generic, custom, and catalog peptides, as well as offers other services. The company is also developing AGM-331 targeted for anti-cancer therapy, currently under pre-clinical development phase; AGM-130 indicated for the treatment of triple negative breast cancer, currently under Phase I development phase; AGM-380 indicated for the treatment of viral infection, currently under pre-clinical development phase; and AGM-290 indicated for the treatment of infections caused by multidrug resistant bacteria, currently under pre-clinical development phase.
Anygen Co., Ltd. Fundamentals Summary
| A196300 fundamental statistics | |
|---|---|
| Market cap | ₩41.66b |
| Earnings (TTM) | -₩8.67b |
| Revenue (TTM) | ₩6.12b |
6.7x
P/S Ratio-4.7x
P/E RatioIs A196300 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A196300 income statement (TTM) | |
|---|---|
| Revenue | ₩6.12b |
| Cost of Revenue | ₩9.48b |
| Gross Profit | -₩3.37b |
| Other Expenses | ₩5.30b |
| Earnings | -₩8.67b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.44k |
| Gross Margin | -55.09% |
| Net Profit Margin | -141.76% |
| Debt/Equity Ratio | 91.6% |
How did A196300 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/07 08:24 |
| End of Day Share Price | 2025/02/07 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Anygen Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.